Connecting Pharma with Ecosystem Innovation
Pharma innovation is evolving to serve a new generation of more connected and informed patients. A new ecosystem of digital-first therapies, devices, platforms and data is emerging from fast-moving partnerships between the biggest pharma players and nimble tech start-ups.
Tomorrow’s Pharma leaders are looking two steps ahead – beyond their immediate digital tech innovation initiatives and towards the connected future of Ecosystem Innovation.
We can help you join them.
1. The new digital dimension to Pharma innovation
Innovation has always been the mechanism by which pharma companies like yours developed drugs and advanced therapies to improve patient outcomes.
But today’s patients are more informed, empowered and connected to their personal health journey. They want more than the solely drug-based treatments traditional research and development was built to serve.
Industry leaders are adding a new digital dimension to pharma innovation – supplementing traditional drug development with new connected treatments, devices, therapies and services built around individual and disease specific patient needs.
The very business of Pharma is changing - and tomorrow’s biggest winners will be the companies that think more like connected health providers rather than exclusively as drug developers.
That means pharma leaders are making digital innovation a core competency – by integrating established expertise with new thinking, in order to:
● Combine clinical expertise with new digital technology innovation in drug development.
● Balance digital acceleration with compliance, security and patient safety.
● Embed digital technologies in their portfolio to support patient-centricity.
● Develop a clear business case for digital health solutions built around patient needs.
● Explore new business opportunities through connected health solutions in collaboration with partners and startups.
Zühlke unites technology, business and user experience expertise to help players in highly regulated industries adopt and operationalize high-impact digital innovation.
For Pharma, we’ve developed a specific framework designed to transform the industry’s biggest digital innovation ideas into robust, compliant, and patient-centric solutions and services.
We call it Ecosystem Innovation.
2. Ecosystem Innovation
Ecosystem Innovation is a framework to accelerate digital maturity in pharma innovation initiatives. Whether you’re looking to digitally enhance your existing offerings, or accelerate entirely new digital-first solutions, Ecosystem Innovation can help:
- Drive patient-centric innovation
- Build clear business cases for digital initiatives
- Expand siloed innovation success into a coherent digital strategy
- Support integration into the growing end-to-end health ecosystem
Connected, ecosystem-optimized digital initiatives are the fastest path for pharma-tech players to create high-value, future-proof, patient-first outcomes.
As the most successful pharma innovators scale up towards (full) tech maturity, we’ve distilled six best-practice principles that set up innovation initiatives for long-term success.
ePaper "6 Principles powering Digital Health and the patient journey evolution"
Pharma-tech frontrunners are using a new model for digital change. We call it Ecosystem Innovation – get started with our ePaper.
The outcomes of Ecosystem Innovation
Ecosystem Innovation can accelerate your pharma-tech innovation success, by helping you:
- Identify operational and organizational changes needed to support new offerings
- Integrate new solutions across the whole patient journey
- Scale proofs of concept to full solutions
- Build robust, stable, secure cloud architecture
The result? An innovation methodology that:
- Accelerates innovation, safely.
We’ve helped organizations working in complex and highly-regulated industries maximize their returns on digital tech innovation – and brought those insights and experiences to Pharma.
- Prioritizes your innovation goals.
Opportunity abundance can be paralyzing. We help pharma companies rationalize a universe of new potential into specific, ecosystem-ready technology capabilities that drive high-impact business outcomes.
- Builds your innovation expertise.
We offer expert support on your innovation journey. Across every partnership we help you develop skills, teams, experience, and processes that deliver long-term value.
- De-risks your innovation processes.
Pharma is just one of the highly regulated industries in which we’ve helped businesses leverage technology to drive business model change. Working with Zühlke keeps regulatory compliance paramount.
3. Unlocking AI in Pharma with Ecosystem Innovation
How to seize the AI opportunity in Pharma
Artificial intelligence (AI) is one of the greatest potential sources of digital acceleration for pharma-tech partnerships.
It’s already revolutionizing patient-centric innovation in non-clinical settings. But it also has huge potential to:
- Accelerate drug development.
- Advance patient stratification for clinical trials
- Bring pharma companies closer to patients, physicians, and other players in the health ecosystem
- Improve both business and patient outcomes
- Support pharmaceutical companies to engage in the field of prevention – and evolve into a provider of health
Unfortunately, the path forward isn’t always clear. Patient (or clinical trial) ready AI-based solutions need to be developed within a strict regulatory framework.
The obstacles – and how we can help you overcome them
The potential for AI in clinical applications is self-evident. But there is still regulatory uncertainty around how to safely and securely leverage AI for cases using software as a Medical Device (SaMD).
Move too fast, or break too many things, and you’ll lose money, time, and worst of all – patient trust.
Look no further than the 2019 example – where a racial bias was found to infect a commonly used healthcare algorithm in the US – to see how damaging such mistakes can be. To help you avoid catastrophes like this, we developed five principles for applying AI in Pharma and life sciences, which you can read here.
These principles are based on our experience working with life science and pharmaceutical companies to bring AI-led solutions to market.
Our medical AI approach
The five principles also form the backbone of our Intelligent Health service which helps organizations develop compliant AI solutions for medical applications. Our solutions integrate with medical software for specific therapeutic areas and patient cohorts.
Curious to learn more?
AVA Women wanted to enhance their fertility tracking bracelet so it could be used for other indications.
This meant their machine learning-based algorithm became a class IIb medical product and required clearance by a notiﬁed body. Zühlke provided consultation to AVA Women, helping them ensure their product development fulfilled the regulatory demands.
4. Digital Health Platforms: Ecosystem Innovation is ready for the sleeping giant
Building for the future
Digital Health Platforms are the bedrock for a future of more connected end-to-end patient experiences.
Isolated solutions in healthcare can’t meet new patient demands. Pharma’s patient-centric and outcome basedoutcome-based future depends on an ecosystem of interconnected data sources, enabled by Digital Health Platforms.
However, while Digital Health Platforms are near the top of the long-term strategic agenda for many pharma players, near-term progress is limited.
The challenge is to reconcile a huge legacy IT infrastructure with new ecosystem demands. That’s why the key to acceleration towards the Digital Health Platform future is to start small and build smart.
But, just like AI in Pharma, you need to explore and validate your opportunities before you can accelerate towards them – and that starts with assessing your current capability gaps against the features and restrictions of DHP vendors.
The obstacles – and how we can help you overcome them
Digital fragmentation – like disconnected systems and siloed patient data – is a major impediment to the connectivity that DHPs rely on.
The key to attack this fragmentation is to incorporate smaller digitization projects into a long-term and incremental platform strategy that breaks down your overall DHP vision into smaller manageable milestones.
Our Connected Health service helps pharma companies identify and resolve the obstacles of digitization that impact long-term platform strategies.
With our interdisciplinary insight, we can highlight integration challenges – and opportunities – across organizational boundaries, allowing you to build towards a future of interconnected healthcare. Only once this integration layer is ready, will solutions which leverage the Internet of Medical Things (IoMT) create meaningful impact throughout the patient journey, from clinical trials through to treatment pathways.
Our deep experience working with IoMT coupled with our interdisciplinary market insight, allows us to translate future business models to fit product portfolio specifications, preempt future pain points for our clients, help them realize their goals, and reimagine their solution portfolio using smart connected devices.
This insight is the foundation of our Connected Health service.
Curious to learn more?
A global medical company wanted to improve their products and offer new services by adding connectivity to their devices.
This meant they needed to make technology and architecture choices that ensured safety and security. Zühlke ran several workshops, performed a threat analysis, and provided a software, security, and system architecture proposal which resulted in a complete concept ready to be developed
Join us at the latest Zühlke events
In addition to our events, we love to connect directly with new pioneers, ready to make meaningful and informed strides into these emerging pharma markets.
So if you’re ready to enrich your innovation journey, let’s connect and talk about how we turn the unknown future into the strategic present.
Albert Frömel is responsible for the Healthcare & Life Sciences sector in Austria He draws on years of experience with leading national and international health institutions. In doing so, he actively helped shape the solution to the most important digital challenges. His focus is on digital transformation, new intelligence systems and data-driven ecosystems. Together with his team, he empowers his clients to improve patient health outcomes, modernize work environments and ensure future-proof business models. Albert Frömel completes his technical education with a degree from the Vienna University of Economics and Business Administration and regularly gives lectures at conferences.
Bardia M. Zanganeh
Bardia M. Zanganeh is responsible for the Life Sciences and Healthcare practice in Switzerland. He serves leading healthcare institutions on all technology agenda issues. His primary areas of focus include digital innovation, business model transformation and product innovation. He also serves providers as well as medical technology and pharmaceutical companies. He has a background in engineering, consulting and entrepreneurship and is a lecturer at the University of Applied Sciences in Business Administration in Zurich.
Nicolas oversees the Healthcare and MedTech vertical at Zuhlke Singapore. As part of the Business Development team, he works on digital innovation initiatives together with both global and local customers. Nicolas finds joy in helping clients connect the dots, from conceptualisation to creation of exciting products.
Acting as innovation partner, Jan-Philipp supports companies in regulated markets such as the pharmaceutical and banking sectors in developing data-driven business models and digital solutions and processes. He brings experience as a consultant from a technology and management consulting firm and has the relevant industry insights from his previous roles at a digital health startup and a financial services company.